A 6-month-old infant with confirmed classic phenylketonuria (PKU) is brought to the metabolic clinic. Plasma phenylalanine is 850 µmol/L (target <360 µmol/L on diet), and the mother reports poor adherence to the phenylalanine-restricted diet due to difficulty obtaining medical foods. The infant has normal development so far, but you are concerned about long-term neurological outcomes. What is the most appropriate immediate next step?

Explanation

## Clinical Context: PKU Management—Addressing Non-Adherence This is a **management problem**, not a diagnostic one. The infant has confirmed classic PKU with suboptimal metabolic control (Phe 850 µmol/L vs. target <360 µmol/L). The root cause is **poor dietary adherence due to access barriers**—not a biochemical failure of the diet itself. ### The Core Issue: Adherence, Not Diagnosis **Key Point:** In PKU management, the **primary modifiable factor** is adherence to the phenylalanine-restricted diet. Suboptimal Phe levels in an infant who is otherwise developing normally, with a documented access barrier, require **removal of the barrier** (dietitian support, food access programs) before escalating to additional pharmacotherapy. ### Why Dietary Counselling + Support is the Next Step **High-Yield:** The NEET PG examiners test whether you recognize that: 1. **Dietary management is first-line** for classic PKU—it is the most effective and safest intervention 2. **Sapropterin is reserved for**: - Patients with BH₄-responsive PKU (30–50% of cases) - Patients with documented poor dietary adherence *despite* adequate access and counselling - Patients with residual enzyme activity 3. **Adherence barriers** (cost, availability, cultural factors) must be addressed before adding drugs **Clinical Pearl:** In resource-limited settings (common in India), **pharmaceutical assistance programs** and **dietitian-led home visits** are cost-effective, evidence-based interventions that improve outcomes more than adding expensive medications to an already-uncontrolled diet. ### Phenylalanine Control Targets by Age | Age Group | Target Plasma Phe (µmol/L) | Rationale | |-----------|---------------------------|----------| | Newborn–12 months | <360 | Critical period for brain development | | 1–12 years | <360–600 | Continued myelination and cognitive development | | >12 years | <600–900 | Reduced neuroplasticity; some relaxation acceptable | | Pregnant women with PKU | <360 | Prevent maternal PKU syndrome in fetus | **Current patient:** 850 µmol/L at 6 months is **above target** → requires intervention. ### Management Algorithm for Suboptimal Control ```mermaid flowchart TD A["PKU patient with Phe above target"]:::outcome --> B{"Dietary adherence?"}:::decision B -->|Poor adherence| C{"Cause of poor adherence?"}:::decision C -->|Access barrier<br/>Cost, availability| D["Refer to dietitian<br/>Arrange home visits<br/>Access food programs"]:::action C -->|Knowledge gap| E["Intensive dietary counselling<br/>Cooking classes, recipes"]:::action C -->|Acceptability issue| F["Reformulate diet<br/>Newer medical foods"]:::action B -->|Good adherence| G{"Phe still high?"}:::decision G -->|Yes| H["Test BH₄ responsiveness<br/>Consider sapropterin"]:::action G -->|No| I["Continue current diet<br/>Monitor quarterly"]:::outcome D --> J["Recheck Phe in 4–6 weeks"]:::action E --> J F --> J H --> K{"BH₄ responsive?"}:::decision K -->|Yes| L["Start sapropterin"]:::action K -->|No| M["Optimize diet further"]:::action ``` **Tip:** In exam scenarios involving **non-adherence or access barriers**, the next step is always to **address the barrier** (counselling, referral, support programs) before escalating to additional pharmacotherapy.